Dune Medical Devices has grabbed headlines with its cancer-detecting MarginProbe device, and now it's in the crosshairs of Sysmex Corporation, according to a report, with the Japanese company considering a $200 million acquisition.
As Israel's Ynetnews reports, Sysmex is in talks to buy the Caesarea, Israel-based company, which is creeping toward FDA approval for its lumpectomy device. A Dune spokesman didn't respond to requests for comment Tuesday morning.
MarginProbe is designed to minimize the need for repeat operations after breast-conservation surgeries by detecting the presence of cancer at or near the surface of excised tissue. In a recent study, the device cut the rate of re-excision by 50%, promising to save patients time and money.
Dune filed for FDA approval in 2011 and got a 10-1 panel vote in its favor over the summer. The company has said it will work closely with the agency through the rest of the approval process, looking to get MarginProbe on the market as soon as possible.
Sysmex, headquartered in Kobe City, Japan, specializes in hematology and in vitro diagnostics, selling its products in more than 170 countries.
- read the story